Received Oct 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19-2 | COVID19 (COVID19 (MODERNA BIVALENT)) | MODERNA | 5 | — | — |
COVID; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID) in a 70-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis. Previously administered products included for Drug use for unknown indication: Nucala (Used to be on Nucala). Past adverse reactions to the above products included No adverse effect with Nucala. Concurrent medical conditions included Asthma and Allergy NOS (Highly allergic to different things). On 22-Sep-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In November 2022, the patient experienced COVID-19 (COVID). At the time of the report, COVID-19 (COVID) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In November 2022, SARS-CoV-2 test: (Positive) Home test as well as pharmacy. Concomitant medication use information was not provided by reporter. The current age of the patient was reported as 73-year-old. Treatment medication use information was not provided by reporter. This case was linked to MOD-2021-026563 (Patient Link).
Allergy NOS (Highly allergic to different things); Asthma
Test Date: 202211; Test Name: COVID-19 test; Test Result: Positive